Covid19 Clinical Trial
Official title:
The Effect of Behaviour Change Interventions on Use of Public Handwashing Stations in Bangladesh
NCT number | NCT04765540 |
Other study ID # | 2020091 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 3, 2021 |
Est. completion date | May 6, 2021 |
Verified date | July 2021 |
Source | The Behavioural Insights Team |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
As part of the COVID-19 response, BRAC has built 1000 public handwashing stations in several hundred villages in 20 sub-districts of Bangladesh. The investigators investigate the effects of two sets of behavioural interventions on use of the handwashing stations, compared to no additional interventions. The first set comprises passive nudges installed on and around the handwashing station, aimed at attracting people to the station. The second set comprises actively delivered higher-intensity interventions, including free soap offered as an incentive for using the handwashing station and a community board used to display social proof. This set of interventions aims to increase motivation to use the station.
Status | Completed |
Enrollment | 855 |
Est. completion date | May 6, 2021 |
Est. primary completion date | May 6, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Note: the sample consists of villages that have received at least one public handwashing station from BRAC, rather than human participants, though the investigators are measuring the use of the stations by human participants. The initial sample of villages has been chosen from a set of 1,899 villages identified by BRAC as being eligible for this project based on criteria related to COVID-19 cases, existing BRAC programs and village characteristics. The villages are spread across 3 of Bangladesh's 8 divisions, 8 of its 64 districts, and 20 of its 492 subdistricts ('upazilas'). While most of the 'villages' are located in rural parts of Bangladesh, roughly 15 percent are better characterised as wards or towns within urban and peri-urban municipalities. Inclusion Criteria: Villages identified by BRAC as being eligible for this based on: - COVID-19 cases - Existing BRAC programs - village characteristics - viable location for a handwashing station (space/water source) - local community members willing to 'sponsor' and maintain handwashing station Exclusion Criteria: - Lack of viable location for a handwashing station. - Villages that received handwashing stations as part of the pilot phase - Villages randomly selected in a related impact evaluation measuring the impact of the stations themselves |
Country | Name | City | State |
---|---|---|---|
Bangladesh | BRAC | Dhaka | |
Bangladesh | BRAC Khulna | Khulna | |
Bangladesh | BRAC Mymensingh | Mymensingh |
Lead Sponsor | Collaborator |
---|---|
The Behavioural Insights Team | Brac, BRAC Institute of Governance and Development, D2 Technologies Ltd, Bangladesh, Foreign, Commonwealth and Development Office, U.K., Unilever U.K. Central Resources Limited |
Bangladesh,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Average number of people nearby handwashing station per hour (subsample of handwashing stations and villages) | Enumerators will count the number of people within a 10 meter radius of handwashing stations in pre-specified periods during the day. | 2 weeks post-intervention (exact timing will vary by station) | |
Other | Percent of people nearby handwashing station observed to use handwashing station (subsample of handwashing stations and villages) | 2 weeks post-intervention (exact timing will vary by station) | ||
Other | Percent of people nearby handwashing station observed to be wearing face masks and coverings (subsample of handwashing stations and villages) | 2 weeks post-intervention (exact timing will vary by station) | ||
Other | Proportion of handwashing station users who are repeat users (subsample of handwashing stations and villages) | This will be measured by surveying members of the public who pass by the handwashing stations or are observed to use them. The investigators will record participant's reported past use of the handwashing station as well as their observed use during the survey session. | 4 weeks post-intervention (exact timing will vary by station) | |
Primary | Average handwashing station soap pedal presses per day (in weeks 1 to 3) | The investigators will use the number of times the soap pedals on the handwashing stations are pressed as a proxy measure of the frequency of use of the handwashing station for handwashing with soap. This data will be collected via mechanical tally counters ('clickers') connected to the soap pedals such that their count increments when the soap pedal is pressed. The clicker counts will be recorded at 4 points each day for 5 days per week. The investigators will use this information to infer the average number of soap pedal presses per day in the three weeks after the T2 and T3 interventions are first installed or delivered.
The investigators will also attempt to translate this outcome to an estimate of the number of times the handwashing station was used per day, by correlating soap pedal presses with counts of handwashing station users gathered via structured observations in 3 half-hour periods each day. |
At the end of 3 weeks post-implementation | |
Secondary | Average handwashing station soap pedal presses per day (in weeks 4 to 6) | This outcome will be measured identically to the primary outcome, but measures usage over the slightly longer term (the second three-week period after the T2 and T3 interventions are first installed or delivered).
The investigators will also attempt to translate this outcome to an estimate of the number of times the handwashing station was used per day, by correlating soap pedal presses with counts of handwashing station users gathered via structured observations in 3 half-hour periods each day. |
At the end of 6 weeks post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |